Last reviewed · How we verify
NCT07056803
Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus
trial testing Oral semaglutide in Diabetes Mellitus Type 2 in 212 participants. Completed in 25 June 2025.
25 June 2024
Quick facts
| Lead sponsor | University of Palermo |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 212 |
| Start date | 1 January 2024 |
| Primary completion | 25 June 2024 |
| Estimated completion | 25 June 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Oral semaglutide
- subcutaneous semaglutide — full drug profile →
Conditions studied
- Diabetes Mellitus Type 2 — all drugs for Diabetes Mellitus Type 2 →
Sponsor
University of Palermo
Who can join
18 and older, any sex, with Diabetes Mellitus Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This real-world, comparative cohort study aims to evaluate the 12-month effectiveness of oral versus subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2D), with a specific focus on sex-based differences in metabolic response. A total of 212 patients were enrolled and evenly assigned to either oral or subcutaneous semaglutide. The primary outcome was the change in HbA1c, while secondary outcomes included variations in weight, lipid profile, liver function, and hepatic steatosis index. Subcutaneous semaglutide resulted in greater improvements in HbA1c, weight, and LDL cholesterol in men, while women exhibited a more favorable hepatic response. These findings support the need for sex-specific considerations in T2D therapy personalization.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07056803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oral semaglutide
Trials testing the same drug.
- NCT07390110 — Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejectio · active not recruiting
- NCT07271251 — A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the · Phase 3 · active not recruiting
- NCT06659718 — Emulation of the SOUL Diabetes Trial in Healthcare Claims · completed
- NCT05443568 — A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinic · completed
- NCT05502562 — A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India · completed
Other recruiting trials for Diabetes Mellitus Type 2
Currently open trials in the same condition.
- NCT07011147 — Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery · NA · recruiting
- NCT07420634 — Multilevel Ecological and COM-B Determinants of Medication Adherence in Adults With Diabetes · recruiting
- NCT07114822 — HOPE Intervention for Fitness · NA · recruiting
- NCT07245082 — Patients With Type 2 Diabetes · recruiting
- NCT07065383 — Rebalancing the Fat Content of the Heart and Muscles · NA · recruiting
Other University of Palermo trials
Trials by the same sponsor.
- NCT03017716 — Inflammatory Back Pain and Gluten Free Diet · NA · not yet recruiting
- NCT07364149 — Acute Effects of Structured Exercise and Static Stretching on Vascular Function, Neuromuscular Performance, and Metaboli · NA · recruiting
- NCT06206616 — Liver Steatosis in Pediatric CD Patients · not yet recruiting
- NCT07433543 — Foam Rolling, Blood Pressure and Range of Motion · NA · completed
- NCT07213011 — Effects of Static Stretching and Self-myofascial Release on Local and Remote Range of Motion · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07056803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Palermo
- Last refreshed: 17 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07056803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing